Group 1 - The core point of the article is that Fuioupay is making its fourth attempt to list on the Hong Kong Stock Exchange, facing challenges related to compliance issues and significant dividend payouts [2][3][8] - Fuioupay has a history of failed listing attempts, with its first application submitted in April 2024, followed by three subsequent applications that also failed [2][3] - The company has been planning for an IPO for over ten years, having signed various advisory agreements with different securities firms since 2015 [2] Group 2 - Fuioupay is a comprehensive digital payment technology platform established in July 2011, recognized as a pilot provider of multi-channel digital payment and digital business solutions in China [4] - The company has developed a wide range of payment services, including commercial payments, financial payments, and cross-border digital payment services, connecting with major card organizations and banks globally [4] - In 2024, the total payment volume (TPV) of China's digital payment service market was 268.6 trillion yuan, with Fuioupay holding a market share of 0.8% among comprehensive digital payment service providers [5] Group 3 - Fuioupay's financial performance shows revenue growth but fluctuating profits, with revenues of 1.142 billion yuan in 2022, 1.506 billion yuan in 2023, and 1.634 billion yuan in 2024, while net profits were 71.17 million yuan, 92.98 million yuan, and 84.43 million yuan respectively [5] - The company's gross profit margins have declined from 28.4% in 2022 to 25.8% in the first ten months of 2025 [5] - The company has incurred significant costs, with sales and distribution expenses, R&D expenses, and administrative expenses totaling over 1 billion yuan in recent years [6] Group 4 - Fuioupay has distributed a total of 365 million yuan in dividends from 2021 to 2025, which exceeds its net profits during the same period, raising questions about the necessity of its IPO [7][10] - The company has faced multiple compliance issues, including fines totaling 6.66 million yuan for various violations, which may hinder its IPO prospects [12][14] - Consumer complaints against Fuioupay have been significant, with over 1,700 complaints reported, primarily concerning unauthorized charges and refund difficulties [15]

Core Viewpoint - Mingguang Rierjinda Technology Co., Ltd. has successfully passed the listing review by the Beijing Stock Exchange, moving closer to its IPO despite challenges in the steel industry, showcasing a gross margin of nearly 40%, which is more than double the industry average [1][24]. Group 1: Company Background and Leadership - The actual controllers of Rierjinda are Xu Ruitu and his daughter Xu Xiaohan, with Xu Ruitu having extensive experience in the refractory materials industry [1][6]. - Xu Ruitu founded Beijing Rier in 2002 and has led the company to significant milestones, including its recent listing on the New Third Board in December 2023 [4][25]. - Xu Xiaohan, with an educational background from prestigious institutions, holds multiple key positions within the company, including Vice Chairman and Secretary of the Board [6][27]. Group 2: Financial Performance and Dividend History - Rierjinda's financial history shows a high dividend payout, with a total of approximately 2.33 billion yuan distributed in dividends from 2020 to mid-2023, despite a net profit of only about 1.3 billion yuan during the same period, resulting in a dividend payout ratio of 179% [1][28]. - The company plans to raise 335 million yuan through its IPO, having previously aimed for 473 million yuan, indicating a strategic adjustment in its fundraising approach [10][33]. - The gross margin of Rierjinda has consistently been high, with figures of 32.26%, 37.74%, 39.72%, and 39.09% over the reporting periods, significantly exceeding the average of comparable companies [15][39]. Group 3: Market Position and Client Dependency - Rierjinda's client base is highly concentrated, with the top five customers accounting for over 40% of total sales, including major steel companies like Baowu Group and Shougang Group [1][19]. - The company has faced increasing accounts receivable, which reached 2.41 billion yuan in mid-2025, representing 106% of its revenue for that period, indicating potential liquidity concerns [19][43]. - Rierjinda's revenue growth has been questioned due to the declining production of refractory materials in the industry, yet the company attributes its growth to stable demand from existing customers [13][37]. Group 4: Future Prospects and Risks - The company plans to invest in projects aimed at enhancing its production capabilities and developing new technologies, although some proposed products have not yet generated revenue [21][45]. - Rierjinda's high gross margin and concentrated customer base raise concerns about its long-term sustainability and governance, which will need to be addressed post-IPO [21][45].

Core Viewpoint - Two companies, Lianxun Instrument and Ruili Jieda, successfully passed the IPO review on January 14, 2026, marking significant milestones for both firms in their respective sectors [1][2]. Company Summaries Lianxun Instrument - Lianxun Instrument is the first company to be reviewed for the Sci-Tech Innovation Board in 2026, focusing on advanced technology and core competitiveness during the review process [2][3]. - The company adjusted its fundraising target from 1.954 billion yuan to 1.711 billion yuan after addressing inquiries regarding the necessity of its fundraising projects [2][3]. - The updated prospectus indicates that Lianxun Instrument has canceled the "supplementary working capital" project, reducing the total fundraising amount [2][3]. Ruili Jieda - Ruili Jieda, which provides technology solutions and key refractory materials for blast furnace systems, has undergone a second attempt to list on the Beijing Stock Exchange after previously withdrawing its application due to strategic adjustments and market conditions [5][12]. - The company reported a continuous increase in revenue and net profit during the reporting period, with net profits of 23.73 million yuan, 26.96 million yuan, 54.96 million yuan, and 24.31 million yuan from 2020 to mid-2023 [12][14]. - Ruili Jieda's dividend distribution raised regulatory concerns, as the total cash dividends exceeded 80% of the net profit during the reporting period, leading to scrutiny from the exchange [15][14]. - The company has revised its fundraising projects, eliminating a 100 million yuan working capital project and reducing the scale of other projects in its second IPO application [16][18]. Financial Performance Lianxun Instrument - The company plans to invest in several projects, including next-generation optical communication testing equipment and automotive chip testing equipment, with total investment amounts reaching 195.37 million yuan [3][4]. Ruili Jieda - Ruili Jieda's financial performance showed a steady increase in revenue, with figures of 403 million yuan, 467 million yuan, and 476 million yuan from 2022 to 2024, alongside net profits of 54.96 million yuan, 77.21 million yuan, and 79.44 million yuan during the same period [18][19]. - The company has forecasted a slight increase in revenue and net profit for 2025, projecting revenues of 479.63 million yuan and net profits of 89.34 million yuan, indicating a growth trend despite market challenges [23].

Core Viewpoint - Guangdong Hengjin Metal Co., Ltd. (referred to as "Hengjin Metal") has submitted an application for listing on the Beijing Stock Exchange, but its "clear-out dividend" strategy may pose a significant obstacle to its IPO due to excessive cash dividends that raise concerns about the authenticity of its financial disclosures [1][5][19]. Financial Performance - Hengjin Metal's revenue and net profit have shown significant fluctuations, with revenue of 9.5 billion yuan in 2022, 8.44 billion yuan in 2023, and projected growth to 10.19 billion yuan in 2024, while net profit figures were 1.14 billion yuan, 0.94 billion yuan, and expected to rise to 1.15 billion yuan in 2024 [3][16][17]. - The company has implemented cash dividends totaling 264 million yuan over the last three years, which accounts for 81.73% of its net profit of 323 million yuan during the same period, exceeding the 80% threshold set by regulatory guidelines [4][18][19]. Dividend Concerns - The cash dividends have raised questions regarding the authenticity of financial disclosures, as discrepancies exist between the reported dividend amounts in the prospectus and previous filings, particularly regarding the 2022 dividend of 24.885 million yuan [5][21]. - The majority of the cash dividends have flowed to the controlling shareholder, Junhui International, and its affiliates, leading to a significant reduction in the company's cash and assets [1][8][22]. Research and Development - Hengjin Metal has the lowest R&D expense ratio compared to its peers, with R&D expenses of 20.637 million yuan in 2022, representing only 2.17% of revenue, while the average for comparable companies exceeds 3% [15][23][24]. - The company attributes its low R&D expense ratio to the sale of metal waste generated during R&D activities, which reduces the reported costs [24][25]. Sales Performance - The company relies heavily on export sales, with export revenue accounting for over 55% of total revenue in recent years, and the gross margin for export sales significantly exceeds that of domestic sales, with a difference of 18-27 percentage points [10][25][26]. - The gross margin for export sales was reported at 30.44% in 2022, while domestic sales only achieved a margin of 12.65% [10][25]. Control and Governance Issues - The actual controller of Hengjin Metal, Sun Zhiheng, has been declared legally incapacitated, raising questions about the governance and decision-making capabilities within the company [12][27][28]. - Despite being recognized as the actual controller, concerns remain regarding whether Sun Zhiheng can effectively protect the company's interests and make significant strategic decisions [27][28].

Core Viewpoint - Sinovac Biotech, once a leading player in the vaccine industry, is facing a severe delisting crisis due to a prolonged internal power struggle rather than market competition or business decline [1] Group 1: Company Background - Sinovac Biotech was founded in 2001 by Yin Weidong and Pan Aihua, combining technical expertise and capital investment [2] - The company expanded its product line from hepatitis A vaccine to various vaccines, including those for influenza and SARS [2][3] - Sinovac successfully went public on NASDAQ, but internal conflicts began to emerge as the company grew [3] Group 2: Internal Conflicts - Fundamental disagreements arose between the founders regarding the ownership and control of the company, leading to factionalism among shareholders [3] - The conflict escalated in 2018, resulting in physical altercations at the company’s facilities and significant financial losses, including the destruction of 6 million vaccine doses [3] - NASDAQ suspended trading of Sinovac shares in 2019 due to the company's failure to provide required information, leading to a stagnant stock price of $6.47 and a market cap of approximately 28 billion RMB [3] Group 3: Financial Performance and Dividends - The COVID-19 pandemic provided a temporary revival for Sinovac, with the company earning a net profit of $8.46 billion (approximately 600 billion RMB) in 2021 from its vaccine [4] - Despite the financial success, internal disputes meant that not all founders benefited equally, with Pan Aihua receiving no dividends and facing legal issues [4] - A controversial "liquidation-style dividend" proposal was introduced, offering up to $124 per share, totaling around 74.4 billion USD (approximately 530 billion RMB), which was overwhelmingly supported by shareholders [6] Group 4: Current Situation and Future Outlook - The company is currently in a precarious position, having failed to publish its annual report on time, leading to NASDAQ's decision to delist it on November 21 [6][7] - Sinovac has appealed the delisting decision, but the situation appears more dire than previous instances [6][7] - The internal power struggle has left the company in a state of decline, with no clear winners among the founders or shareholders [7]

Core Viewpoint - Yuwang Bio is facing significant financial challenges, including a 74% drop in net profit and high debt levels, while also engaging in controversial dividend practices that may jeopardize future shareholder interests [1][6][9]. Financial Performance - Yuwang Bio reported revenues of 5.34 billion, 6.61 billion, 8.32 billion, and 3.43 billion for the years 2022 to 2025 H1, with net profits of 0.67 billion, 1.02 billion, 1.25 billion, and 0.23 billion respectively, indicating a 27.13% decline in revenue and a 74.01% decline in net profit for 2025 H1 compared to the previous year [3][5]. - The company's gross profit margins decreased from 25.4% in 2022 to 20.7% in 2025 H1, contributing to the decline in net profit [3][5]. Market Position - Yuwang Bio is the largest supplier of food-grade refined fish oil globally, holding an 8.1% market share as of 2024 [3][5]. - The global market for food-grade fish oil has experienced a compound annual growth rate (CAGR) of -6.76% from 2020 to 2024, with a projected CAGR of 6.65% from 2025 to 2029, indicating limited growth potential [5]. Debt and Dividend Practices - The company's debt-to-asset ratio was over 90% in 2024 and remained above 83% in 2025 H1, while it declared a controversial dividend of 3.2 billion, exceeding its net profit for the three years from 2022 to 2024 [1][6][9]. - The 3.2 billion dividend was characterized as a "clearance dividend," which is defined as exceeding 80% of net profit over three years, raising concerns about the impact on future shareholder interests [8][9]. Internal Control Issues - Yuwang Bio reported a total of 1.59 billion in illegal bill financing and 2.42 billion in misallocated loan funds, totaling over 4 billion, indicating significant internal control failures [2][10][12]. - The company attributed these violations to a lack of familiarity with regulatory requirements, placing blame on the financial manager, which raises questions about overall governance and internal controls [12][13].

Core Viewpoint - Yuwang Bio Nutrition Co., Ltd. has submitted its IPO prospectus in Hong Kong, revealing significant financial challenges, including a 74% drop in net profit and a high debt ratio, raising concerns about its future profitability and governance practices [1][3][12]. Financial Performance - Yuwang Bio is the largest supplier of food-grade refined fish oil globally, with a market share of 8.1% as of 2024 [3]. - The company's revenue and net profit for the years 2022 to 2025 are as follows: - 2022: Revenue of 534 million RMB, Net Profit of 67 million RMB - 2023: Revenue of 661 million RMB, Net Profit of 102 million RMB - 2024: Revenue of 832 million RMB, Net Profit of 125 million RMB - 2025 (H1): Revenue of 343 million RMB, Net Profit of 23 million RMB - The company experienced a year-on-year revenue decline of 27.13% and a net profit decline of 74.01% in the first half of 2025 [3][5]. Profitability and Margin Issues - The gross profit margin has decreased from 25.4% in 2022 to 20.7% in the first half of 2025, contributing to the decline in net profit [3][5]. - The average selling prices of several core products have significantly dropped: - High-purity fish oil: from 323 thousand RMB/ton to 133 thousand RMB/ton (58.82% decrease) - Medium-purity fish oil: from 158 thousand RMB/ton to 74 thousand RMB/ton (53.16% decrease) - Low-purity fish oil: from 78 thousand RMB/ton to 45 thousand RMB/ton (42.31% decrease) - Fish oil soft capsules: from 155 thousand RMB/ton to 99 thousand RMB/ton (36.13% decrease) [5]. Debt and Dividend Practices - The company's debt ratio was over 90% in 2024 and remained above 83% in the first half of 2025 [7][8]. - Yuwang Bio declared a "clearing dividend" of 320 million RMB, which exceeds the total net profit of 294 million RMB for the years 2022 to 2024, raising concerns about the impact on future shareholder interests [10][11]. Internal Control and Compliance Issues - The company reported a total of 1.59 billion RMB in illegal bill financing and 2.42 billion RMB in misused loan funds, totaling over 4 billion RMB in compliance issues [2][12]. - Yuwang Bio attributed these violations to a lack of understanding of regulatory requirements, which raises questions about its internal governance and control mechanisms [15].

Core Viewpoint - Dong'e Ejiao is experiencing a decline in market confidence despite reporting revenue and profit growth, indicating deeper concerns about its business model and reliance on core products [2][3][8]. Financial Performance - Dong'e Ejiao reported a revenue of 28.45 billion yuan in the first half of 2025, with its core products contributing 93.24% to total revenue, an increase from 91.5% in 2022 [9][10]. - The company announced a cash dividend of 12.69 yuan per 10 shares, totaling approximately 8.17 billion yuan, which accounted for 99.94% of its net profit for the first half of 2025 [7][8]. - Despite the high dividend payout, the stock price fell from around 60 yuan per share in April 2025 to 47.38 yuan by October 10, 2025, marking a cumulative decline of 20.91% [4][5]. Market Dynamics - The Wind Pharmaceutical and Biological Index increased by 25.8% during the same period, contrasting sharply with Dong'e Ejiao's stock performance [5]. - The company faces significant competition from rivals like Fupai Ejiao and Tongrentang, which is impacting its market share [12][23]. Product Dependency and Innovation - Dong'e Ejiao's heavy reliance on its core product, Ejiao, raises concerns about its risk management capabilities, as over 80% of its revenue comes from Ejiao blocks and compound Ejiao syrup [9][10]. - The company has not successfully developed new growth drivers, with new products like "Royal Weichang 1619" and "Zhuangben" still in the incubation stage and projected to generate less than 10 million yuan in sales in 2024 [9][10]. Cost and Pricing Pressures - The gross margin for Ejiao and related products decreased to 74.83% in the first half of 2025, marking the first decline since 2023, primarily due to competitive and cost pressures [10][11]. - The price of donkey hides, a key raw material for Ejiao, has surged over 50% this year, exacerbating cost challenges for the company [13][15]. Inventory and Receivables - Dong'e Ejiao's inventory stood at 920 million yuan, with an increased turnover period of 198 days, indicating slower inventory movement [19]. - Accounts receivable surged by 583.32% in the first quarter of 2025, raising concerns about potential demand weakness and channel inventory issues [20][22]. Industry Trends - The overall market for Ejiao has contracted from 350 billion yuan in 2018 to 280 billion yuan in 2023, driven by high prices and doubts about product efficacy [23].

Core Viewpoint - The company, Xinhua Technology International Limited, has submitted its IPO application for the second time, raising concerns about its financial practices and independence due to significant related-party transactions and a large dividend payout prior to the listing [1][9][13]. Group 1: Company Overview - Xinhua Technology International Limited is primarily engaged in customized software development services, standardized software products, and application hosting services, ranking fourth among service providers in Japan's software technology market [2]. - The company is a subsidiary of Huaxin Technology Co., Ltd., which holds an 86.9% stake, while Itochu Hong Kong and Daiwa Research hold 8.6% and 4.5% respectively [3][6]. Group 2: Financial Performance - For the reporting period from 2022 to 2024, Xinhua reported revenues of 1.632 billion, 1.925 billion, 1.802 billion, and 978 million yuan, with a net profit of 182 million, 270 million, 202 million, and 187 million yuan, showing a significant year-on-year increase of 1994.4% [8]. - The company heavily relies on the Japanese market, with revenue from Japanese clients accounting for 86.3%, 89.8%, 92.6%, and 95% of total revenue during the reporting period [8]. Group 3: Dividend Distribution - Xinhua has engaged in substantial dividend payouts, distributing 233 million yuan in cash dividends in 2024, which accounted for 115.35% of its net profit for that year, indicating a "clear-out" dividend strategy [10][13]. - Cumulatively, the company distributed 251 million yuan in dividends over the reporting period, representing 38.38% of total net profits [10]. Group 4: Related-Party Transactions - The company's major clients are also significant shareholders, raising concerns about potential conflicts of interest and the fairness of related-party transactions [14][17]. - Daiwa Research, a major client, is also a shareholder, holding 4.5% of Xinhua's shares, which complicates the relationship between the company and its clients [14][19]. Group 5: Financial Health and IPO Motivation - Despite having 906 million yuan in cash and a low debt level, the company is pursuing an IPO, leading to questions about the necessity of additional capital and potential motives behind the listing [13][22]. - The company has maintained a healthy financial status with a debt-to-asset ratio of 54.77% and a current ratio of 1.67 as of June 30, 2025 [13].

Core Viewpoint - The article discusses the reasons behind companies with high bank deposits still seeking IPO financing, exploring potential motivations and implications for investors and regulators [1]. Group 1: Mismatched Funding Cycles - High bank deposit balances alongside significant financing do not necessarily indicate financial fraud, as financial statements reflect a specific point in time and have static limitations [2]. - Companies often experience long payment cycles due to industry practices, which can lead to cash flow pressures despite high bank deposits [2][3]. Group 2: Regulatory Scrutiny of Large Dividends - Some companies with substantial bank deposits engage in "clearing-style dividends" before IPOs, creating significant funding gaps in their financial statements [4]. - New regulations set to be implemented in 2024 will scrutinize dividend practices, particularly those where dividends exceed 80% of net profits or where a significant portion of raised funds is used for working capital or loan repayment [4]. Group 3: In-Depth Verification of Bank Deposits - High bank deposit balances may not reflect available funds for operations, as they could be tied up in guarantees or regulatory requirements, or used to mask financial irregularities [5]. - Auditing methods for bank deposits need to be thorough and consider underlying risks, rather than relying solely on standard verification procedures [5]. Group 4: Financing Needs and Market Dynamics - Each company with high deposits has unique financing needs, and establishing a reasonable financing scale is crucial for aligning the interests of capital markets and IPO companies [5].